Boston Scientific (BSX)
(Real Time Quote from BATS)
$76.44 USD
+0.33 (0.43%)
Updated Jul 9, 2024 12:12 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BSX 76.44 +0.33(0.43%)
Will BSX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BSX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BSX
Medtronic Loses 5% in a Month: What's Next for MDT Investors?
Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note
BSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Boston Scientific (BSX) DBS Programming Software Gets CE Mark
Why Boston Scientific (BSX) Dipped More Than Broader Market Today
GE HealthCare (GEHC) Boosts Interventional Radiology Capabilities
Other News for BSX
Buy Rating Justified for Boston Scientific Amidst Positive TCAR Market Adoption and Growth Opportunities
Blackstone’s Voting Power in Corazon Diluted
7 Biotech Stocks to Boost Your Portfolio to Peak Health
3 Record-Breaking Stocks With More Room to Run
RBC Capital Remains a Buy on Boston Scientific (BSX)